@article{457798b52d4f4f45ab4988b79120f9d7,
title = "Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project",
abstract = "Background: Guideline for Pharmacological Therapy for Schizophrenia was published by the Japanese Society of Neuropsychopharmacology in 2015. “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project aimed to standardize medical practice using quality indicators (QIs) as indices to evaluate the quality of medical practice. In this study, we have reported the quality indicator values of prescription before the beginning of the guideline lectures in the EGUIDE project to ascertain the baseline status of treating patients with schizophrenia. Methods: A cross-sectional, retrospective case record survey was conducted, involving 1164 patients with schizophrenia at the time of discharge. We checked all types and dosage of psychotropic drugs. Results: Forty-three percent of patients had antipsychotic polypharmacy, and substantial concomitant medication was observed (antidepressants; 8%, mood stabilizers: 37%, anxiolytics or hypnotics: 68%). Conclusions: In the results obtained in this study, we plant to report changes in the effectiveness of education in the EGUIDE project near the future.",
keywords = "EGUIDE project, antipsychotics, guideline, quality indicator, schizophrenia",
author = "Kayo Ichihashi and Hikaru Hori and Naomi Hasegawa and Yuka Yasuda and Tomoya Yamamoto and Takashi Tsuboi and Kunihiro Iwamoto and Taishiro Kishimoto and Tadasu Horai and Hiroki Yamada and Nobuhiro Sugiyama and Toshinori Nakamura and Naohisa Tsujino and Kiyotaka Nemoto and Satoru Oishi and Masahide Usami and Eiichi Katsumoto and Hidenaga Yamamori and Hiroaki Tomita and Taro Suwa and Ryuji Furihata and Takahiko Inagaki and Junichi Fujita and Toshiaki Onitsuka and Kenichiro Miura and Junya Matsumoto and Kazutaka Ohi and Yuki Matsui and Yoshikazu Takaesu and Naoki Hashimoto and Junichi Iga and Kazuyoshi Ogasawara and Hisashi Yamada and Koichiro Watanabe and Ken Inada and Ryota Hashimoto",
note = "Funding Information: This study was supported by the Japan Agency for Medical Research and Development (AMED) under grant number JP18dk0307060, JP19dk0307083, and JP20dk0307081, Health and Labor Sciences Research Grants (H29‐Seishin‐Ippan‐001, 19GC1201), the Japanese Society of Neuropsychopharmacology, and the Japanese Society of Mood Disorders. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript Publisher Copyright: {\textcopyright} 2020 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of NeuropsychoPharmacology.",
year = "2020",
month = sep,
day = "1",
doi = "10.1002/npr2.12122",
language = "English",
volume = "40",
pages = "281--286",
journal = "Neuropsychopharmacology Reports",
issn = "1340-2544",
publisher = "John Wiley and Sons Inc.",
number = "3",
}
